Table Info

Table 1.

Grading of joint and muscle related adverse events*

irAE	Grade 1	Grade 2	Grade 3	Grades 4–5
Arthralgia¹	Mild pain	Moderate pain; limiting instrumental ADL	Severe pain; limiting self-care ADL	n.a.
Arthritis²	Mild pain with inflammation erythema, or joint swelling	Moderate pain associated with signs of inflammation, erythema, or joint swelling; limiting instrumental ADL	Severe pain associated with signs of inflammation, erythema, or joint swelling; irreversible joint damage	n.a.
Joint effusion³	Asymptomatic, clinical or diagnostic observation only; no intervention needed	Symptomatic; limiting ADL	Severe symptoms; limiting self-care ADL; invasive intervention indicated	n.a.
Myalgia⁴	Mild pain	Moderate pain; limiting instrumental ADL	Severe pain; limiting self-care ADL	n.a.
Myositis⁵	Mild pain	Moderate pain associated with weakness; pain limiting instrumental ADL	Pain associated with severe weakness; limiting self-care ADL	Life-threatening consequences; urgent intervention indicated

*: Extracted from National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0; 2017. Available from (page 95–98): https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. 1: a disorder characterized by a sensation of marked discomfort in a joint. 2: a disorder characterized by inflammation involving a joint. 3: a disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation. 4: a disorder characterized by marked discomfort sensation originating from a muscle or group of muscles. 5: a disorder characterized by inflammation involving the skeletal muscles. CTCAE v5.0 incorporates certain elements of the MedDRA terminology. For further details on MedDRA refer to the MedDRA MSSO Web site (https://www.meddra.org/). MedDRA® the Medical Dictionary for Regulatory Activities terminology is the international medical terminology developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). irAE: immune-related adverse event; ADL: activity of daily living; n.a.: not applicable

Declarations

Author contributions

JB: Investigation, Writing—original draft, Writing—review & editing. KK: Writing—review & editing.

Conflicts of interest

Jürgen Braun who is the Associate Editor and Guest Editor of Exploration of Musculoskeletal Diseases had no involvement in the decision-making or the review process of this manuscript. The other author declares no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254–67. [DOI] [PubMed] [PMC]

Agashe RP, Lippman SM, Kurzrock R. JAK: Not Just Another Kinase. Mol Cancer Ther. 2022;21:1757–64. [DOI] [PubMed] [PMC]

Barron CC, Stefanova I, Cha Y, Elsolh K, Zereshkian A, Gaafour N, et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11:e006500. [DOI] [PubMed] [PMC]

Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients. Arthritis Rheumatol. 2019;71:468–75. [DOI] [PubMed]

Bass AR, Xie F, Jannat-Khah D, Ghosh N, Chan KK, Saxena A, et al. Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study. Rheumatology (Oxford). 2024;keae343. [DOI] [PubMed]

Ghosh N, Jivanelli B, Couette N, Singh N, Kostine M, Meara AS, et al. The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review. Rheum Dis Clin North Am. 2024;50:325–35. [DOI] [PubMed]

Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11:e006398. [DOI] [PubMed] [PMC]

National Cancer Institute. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0; 2017 [Internet]. McLean: meddra.org; c2024 [cited 2024 Aug 30]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf

Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80:36–48. [DOI] [PubMed] [PMC]

10.

Cappelli LC, 3rd COB. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. Arthritis Rheumatol. 2021;73:553–65. [DOI] [PubMed] [PMC]

11.

Singh N, Shahane A, Sparks JA, Bitoun S, Cappelli LC. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management. Rheum Dis Clin North Am. 2024;50:269–79. [DOI] [PubMed]

12.

Reid P, Liew DF, Akruwala R, Bass AR, Chan KK. Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study. J Immunother Cancer. 2021;9:e003260. [DOI] [PubMed] [PMC]

13.

Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435. [DOI] [PubMed] [PMC]

14.

Chan KK, Bass AR. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy. Rheum Dis Clin North Am. 2024;50:337–57. [DOI] [PubMed]

15.

Bruera S, Suarez-Almazor ME. The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol. 2022;12:928390. [DOI] [PubMed] [PMC]

16.

Fuente FDL, Belkhir R, Henry J, Nguyen CD, Pham T, Germain V, et al. Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. RMD Open. 2022;8:e002612. [DOI] [PubMed] [PMC]

17.

Ladouceur A, Barnetche T, Mouterde G, Tison A, Bitoun S, Prey S, et al. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study. RMD Open. 2023;9:e003795. [DOI] [PubMed] [PMC]

18.

Berg MH, Rincón SVD, Miller WH. Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. J Immunother Cancer. 2022;10:e003551. [DOI] [PubMed] [PMC]

19.

Moura RA, Fonseca JE. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis. Front Med (Lausanne). 2020;7:607725. [DOI] [PubMed] [PMC]

20.

Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018;24:47–53. [DOI] [PubMed] [PMC]

21.

Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809. [DOI]

22.

Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science. 2024;384:eadf1329. [DOI] [PubMed] [PMC]

23.

Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL, et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. 2024;384:eade8520. [DOI] [PubMed]

24.

Esfahani K, Hudson M, Batist G. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. N Engl J Med. 2020;382:2374–5. [DOI] [PubMed]

25.

Bishu S, Melia J, Sharfman W, Lao CD, Fecher LA, Higgins PDR. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis. Gastroenterology. 2021;160:932–4.e3. [DOI] [PubMed] [PMC]

26.

Harvey C, Nahar KJ, McKeown J, Lo SN, Farag S, Yousaf N, et al. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer. 2024;12:e008232. [DOI] [PubMed] [PMC]

27.

Wang M, Reynolds KL, Montazeri K, Schaefer EA, Sullivan RJ, Dougan M. Tofacitinib is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis. Clin Gastroenterol Hepatol. 2024;22:1539–41.e2. [DOI] [PubMed]

28.

Sweep MWD, Tjan MJH, Gorris MAJ, Bol KF, Westdorp H. Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib. Front Immunol. 2023;14:1212432. [DOI] [PubMed] [PMC]

29.

Taylor PC, Choy E, Baraliakos X, Szekanecz Z, Xavier RM, Isaacs JD, et al. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology (Oxford). 2024;63:298–308. [DOI] [PubMed] [PMC]

30.

Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82:1059–67. [DOI] [PubMed] [PMC]

31.

Braun J, Karberg K, Poddubnyy D. How to treat a patient with psoriatic arthritis and chronic lymphocytic leukemia? Explor Musculoskeletal Dis. 2024; 2:235–41. [DOI]